-
Yingli Pharma Enrolls First Patient in Phase I Study for KRAS Inhibitor YL-17231 at MD Anderson
Yingli Pharma, a US-based biopharmaceutical company focused on developing therapies for both the Chinese and American markets, has announced the enrollment of its first patient in a Phase I clinical study for YL-17231, a novel pan-KRAS inhibitor targeting malignant solid tumors, at the MD Anderson Cancer Center. This milestone follows…
-
Yingli Pharma’s Linperlislib Receives Priority Review Status for Lymphoma Treatments
US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who…
-
Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US markets, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its investigational drug YL-17231 in the treatment of advanced malignant solid tumors. This follows the previous approval…
-
NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma
The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug, has been conditionally approved in China. The drug is developed by US-based Yingli Pharma, a firm focused on developing products for both the China and US markets. The intended indication for linperlisib is recurrent/refractory (R/R)…
-
Yingli Pharma Doses First Patient in Linperlisib Phase II Trial for PTCL
US-based Yingli Pharma, which targets the China and US drug markets, has dosed the first patient in a Phase II trial of linperlisib, its PI3 kinase (PI3Kδ) inhibitor, for relapsed/refractory peripheral T/NK cell lymphoma (r/r PTCL). The study follows positive Phase I data in China and leverages the drug’s Breakthrough…
